Craft

Telix Pharmaceuticals

Stock Price

$10.4

2024-05-24

Market Capitalization

$3.5 B

2024-05-24

Revenue

$502.5 M

FY, 2023

Telix Pharmaceuticals Summary

Company Summary

Overview
Telix Pharmaceuticals is a company developing molecularly targeted radiation products for cancer care. Its pipeline includes diagnostic and therapeutic products. The company develops drug candidates for the treatment of renal, prostate, and brain cancer.
Type
Public
Status
Active
Founded
2015
HQ
North Melbourne, AU | view all locations
Website
https://telixpharma.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Darren Smith

    Darren Smith, Group Chief Financial Officer

  • Colin Hayward

    Colin Hayward, Group Chief Medical Officer

  • Lena Moran-Adams

    Lena Moran-Adams, General Counsel

  • Michael Wheatcroft

    Michael Wheatcroft, Chief Scientist

Operating MetricsView all

Doses Delivered per Year

13.2K
38.9%

FY, 2021

Active Clinical Studies

20
11.1%

FY, 2022

LocationsView all

8 locations detected

  • North Melbourne, VIC HQ

    Australia

    401/55 Flemington Rd

  • Fishers, IN

    United States

    11700 Exit 5 Pkwy #200

  • Milton, QLD

    Australia

    52 McDougall St

  • Sydney, NSW

    Australia

    Level 11/66 Clarence St

  • Herstal, Wallonie

    Belgium

    Rue de Hermée 255

  • Zaventem, Vlaams Gewest

    Belgium

    Da Vincilaan 1/Floor, Office 916/917

and 2 others

Telix Pharmaceuticals Financials

Summary Financials

Revenue (FY, 2023)
$502.5M
Gross profit (FY, 2023)
$321.3M
Net income (FY, 2023)
$5.2M
Cash (FY, 2023)
$123.2M
EBIT (FY, 2023)
$16.8M
Enterprise value
$3.4B

Footer menu